Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Liso-cel Bests Standard of Care in Second-Line Treatment of LBCL

December 11th 2021

Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment

December 10th 2021

Two new studies by Yale Cancer Center reveal the structure of the molecule known as anaplastic lymphoma kinase, which is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors.

ASH 2021 Is Packed With Practice-Changing Hematologic Cancer Data

December 9th 2021

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

Secura Bio Withdraws Duvelisib Relapsed/Refractory Follicular Lymphoma Indication in the United States

December 6th 2021

Secura Bio, Inc. has decided to voluntarily withdraw the indication of duvelisib for use in patients with relapsed or refractory follicular lymphoma following at least 2 previous systemic therapies.

Pirtobrutinib Provides Promising Results in Richter Transformation

December 6th 2021

Meghan Thompson, MD, discusses the results from the use of pirtobrutinib in the phase 1/2 BRUIN study, as well as upcoming research efforts in the population of patients with Richter transformation.

Liso-cel Significantly Prolongs EFS Over SOC in Second-Line Relapsed/Refractory LBCL

December 3rd 2021

Lisocabtagene maraleucel significantly prolonged event-free survival and progression-free survival and improved complete responses when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma

November 18th 2021

Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.

FDA Grants Fast Track Status to SETD2 Inhibitor EZM0414 for Relapsed/Refractory DLBCL

November 5th 2021

The FDA granted a fast track designation to EZM0414, a first-in-class, oral SETD2 inhibitor, for use as a potential therapeutic option in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Devimistat Granted Orphan Drug Designation in Europe for Relapsed/Refractory Burkitt Lymphoma

November 4th 2021

The European Medicines Agency granted an orphan drug designation to devimistat for the treatment of patients with relapsed or refractory Burkitt lymphoma. The novel compound targets mitochondria in tumor cells.

Dr. Foss on Pursuing New Therapeutic Options in T-Cell Non-Hodgkin Lymphoma

November 3rd 2021

Francine Foss, MD, discusses pursing new therapeutic options for the treatment of patients with T-cell non-Hodgkin lymphoma.

FDA Approval Sought for Parsaclisib in 3 Types of Relapsed/Refractory Non-Hodgkin Lymphoma

November 1st 2021

The FDA has accepted a new drug application for the PI3Kδ inhibitor parsaclisib for use in the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

FDA Grants Priority Review to Tisagenlecleucel for Relapsed/Refractory Follicular Lymphoma

October 28th 2021

The FDA has granted a priority review to tisagenlecleucel for use in adult patients with relapsed or refractory follicular lymphoma.

CAR T-cell Therapy CTX110 Shows Early Promise for Relapsed/Refractory CD19+ B-cell Malignancies

October 13th 2021

The allogeneic CD19-targeted CAR T-cell therapy CTX110 was found to elicit encouraging responses with favorable tolerability in patients with relapsed or refractory B-cell malignancies, according to data from the phase 1 CARBON trial.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Epcoritamab Shows Robust Antitumor Activity, Acceptable Safety in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

September 30th 2021

Epcoritamab had a manageable toxicity profile when subcutaneously administered to patients with relapsed/refractory B-cell non-Hodgkin lymphoma and was found to elicit encouraging responses in those who were heavily pretreated.

Dr. Herrera on the Potential for Frontline CAR T-Cell Therapy in DLBCL

September 20th 2021

Alex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

Zanubrutinib Approaches EU Approval for Waldenström Macroglobulinemia

September 17th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding the use of zanubrutinib in adult patients with Waldenström macroglobulinemia who have previously received at least 1 therapy or in the frontline treatment of patients who are not eligible for chemoimmunotherapy.

FDA Approves Zanubrutinib for Relapsed or Refractory Marginal Zone Lymphoma

September 15th 2021

The FDA has granted an accelerated approval to zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least 1 anti–CD20-based regimen.

Racial, Social Disparities Linked With T-Cell Lymphoma Outcomes

September 11th 2021

Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

September 10th 2021

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.